0001193125-26-100135
SEC filingArtiva Biotherapeutics, Inc. reported a net loss of $83.9 million for fiscal year 2025, with no revenue generated during the period. The company's operations resulted in an operating loss of $89.8 million, driven primarily by research and development expenses of $69.5 million and general and administrative costs of $20.3 million. Other income, primarily from interest income of $6.0 million, partially offset the operating loss. The company ended the year with total assets of $130.9 million, including $26.7 million in cash and cash equivalents and $81.3 million in short-term investments. Total liabilities stood at $21.0 million, resulting in stockholders' equity of $110.0 million. Net cash used in operating activities was $76.8 million, while investing activities provided $63.4 million primarily from investment maturities. The company's financial position reflects its continued investment in research and development activities as a clinical-stage biotechnology company.
Artiva Biotherapeutics, Inc. reported a comprehensive loss of $83.6 million for fiscal year 2025, with a net loss of $83.9 million. The company generated no revenue during the period, consistent with its status as a clinical-stage biotechnology company. Operating expenses totaled $89.8 million, consisting of $69.5 million in research and development costs and $20.3 million in general and administrative expenses. Other income of $5.9 million, primarily from interest income of $6.0 million, partially offset the operating loss. The company reported basic and diluted net loss per share of $3.00, based on weighted average common shares outstanding of 24.4 million.
The company reported no revenue for fiscal year 2025. The document specifically shows license and development support revenue of $0. As a clinical-stage biotechnology company, Artiva Biotherapeutics is focused on research and development activities rather than commercial operations. No segment revenue breakdown or geographic revenue mix is disclosed in the provided data. The absence of revenue reflects the company's pre-commercial stage of development.
With no revenue generated, gross margin and operating margin calculations are not applicable. The company's cost structure is dominated by research and development expenses, which accounted for 77.4% of total operating expenses. General and administrative expenses represented the remaining 22.6% of operating costs. The operating loss margin cannot be calculated as a percentage of revenue due to zero revenue. The company's profitability metrics are limited to net loss figures and loss per share amounts.
Net cash used in operating activities was $76.8 million for fiscal year 2025. Investing activities provided $63.4 million in cash, primarily from $110.9 million in investment maturities offset by $44.9 million in investment purchases. Financing activities provided minimal cash of $9,000. The company ended the year with total cash, cash equivalents and restricted cash of $53.8 million. Total assets stood at $130.9 million, including $112.7 million in current assets. Total liabilities were $21.0 million, resulting in stockholders' equity of $110.0 million and an accumulated deficit of $330.5 million.
The filing does not contain specific forward-looking guidance, management projections, or strategic priorities in the provided data. As a clinical-stage biotechnology company, the primary focus appears to be on research and development activities. The company's financial position shows sufficient liquidity with $112.7 million in current assets against $13.1 million in current liabilities. No specific risk factors or future plans are detailed in the provided financial data sections.